WA-SCHULTZ-FAMILY-FND
13.2.2024 21:54:28 CET | Business Wire | Press release
Trilogy Films, the renowned production company led by award-winning Director Dawn Porter, is thrilled to announce an unprecedented collaboration with the Schultz Family Foundation to produce a feature-length documentary about one of the most iconic, politically-charged partnerships in history: the remarkable, largely untold story of Nelson and Winnie Mandela.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240212248716/en/
Nelson and Winnie Mandela after his liberation from prison in South Africa on February 11, 1990. Photo by Pool BOUVET/DE KEERLE/Gamma-Rapho via Getty Images.
Based on the book by noted South African writer and scholar Jonny Steinberg, Winnie and Nelson: Portrait of a Marriage, the film will explore the Mandelas’ profound bond and how their marriage was inextricably entangled with the struggle against apartheid. The film promises an intimate portrayal of Nelson and Winnie’s marriage, delving into their vehement and volatile connection from their early years to their mutual goal of dismantling apartheid. Their journey culminates in Nelson Mandela’s historic election as South Africa’s first democratically elected President. This cinematic exploration captures the essence of their indomitable spirits and the global impact of their love and advocacy.
Dawn Porter, celebrated for her exceptional storytelling that explores the overlooked, reveals the consequences of policy and social action, champions the marginalized, and offers a fresh perspective on the familiar, is at the helm of the production. With her profound ability to craft narratives that deeply resonate with and inform audiences, Porter is poised to bring a unique lens to the enduring love story of Nelson and Winnie Mandela.
“Creating a film about Nelson Mandela’s life is an extraordinary privilege, and I am genuinely thrilled about the collaboration with the Schultz Family Foundation and Trilogy Films,” said Dawn Porter. “Nelson Mandela’s journey exemplifies the resilience and capacity for change within the human spirit. We aspire to share this incredible odyssey with audiences around the globe. But his story is incomplete without exploring the relationship with his most influential and intimate advisor – his wife Winnie. There can be no definitive Mandela story without understanding the complicated dynamics of their relationship.”
The collaboration with Trilogy Films marks the Schultz Family Foundation’s first venture into transformative storytelling projects – across scripted and documentary films and series, podcasts, and books – linked to its mission of creating greater opportunity, accessible to all. The Schultz Family Foundation’s involvement transcends financial support; it embodies a philanthropic vision and commitment to tell truthful, aspirational stories that have the power to reveal hidden narratives, spark hope, spotlight solutions, and restore confidence during a time of enormous pessimism, dissension, misinformation, and a fracturing of trust in traditional institutions, leadership, and each other.
“At its heart, Winnie and Nelson is a complicated story of leadership, conflict, love, and extraordinary sacrifice in the face of unfathomable brutality where the future of a democracy was at stake,” said Howard Schultz, co-founder of the Schultz Family Foundation and chairman emeritus of Starbucks Corporation. “My wife Sheri and I feel privileged and humbled by the opportunity to partner with such a respected and talented director as Dawn to bring this film to life. We believe in the power of human-centered, aspirational storytelling to nurture our common bonds, foster our shared humanity, and inspire the next generation of leaders, and we look forward to pursuing other projects across many different formats aligned with our family’s philanthropic work and mission.”
About Trilogy Films:
Trilogy Films, founded by award-winning director Dawn Porter, directs and produces non-fiction content that tells untold stories, shares new perspectives, and reveals the complex humanity of some of history’s most iconic figures. Porter's acclaimed films include "Gideon’s Army" (2013), "Spies of Mississippi” (2014), and “Bobby Kennedy for President” (2018). Her latest work, “Luther: Never Too Much,” debuted to rave reviews at the 2024 Sundance Film Festival and was lauded as the best of fest in multiple news outlets. 2023 was a banner year for Porter and Trilogy. The Critics Choice nominated “Lady Bird Diaries," an all archival documentary showcasing Lady Bird Johnson, premiered at the 2023 SXSW Film Festival, while her four-part docuseries "Deadlocked: How America Shaped the Supreme Court” also garnered nominations for a Critics Choice Documentary Award as well as a Film Independent Spirit Award.
About the Schultz Family Foundation:
The Schultz Family Foundation’s mission is to create greater opportunity, accessible to all. Our work is deeply rooted in the lives and values of our co-founders, Sheri and Howard Schultz, who believe talent is everywhere, but opportunity is not. We seek to apply the lessons they have learned over the decades to seed innovations and scale solutions to help young people successfully navigate the transition to adulthood and positively impact the trajectory of their lives. We are investors in unleashing potential and unlocking opportunity, working in partnership with employers, entrepreneurs, non-profits, and governments that share our aspiration of enabling everyone to access the full promise of America. For more information about the Foundation and its work: www.schultzfamilyfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212248716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
